These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24113660)

  • 1. Use of antiplatelet agents in patients with atherosclerotic disease.
    Acharji S; Lakshmanadoss U; Rudzinski W; Stapleton DD; Kaluski E
    Postgrad Med; 2013 Sep; 125(5):19-30. PubMed ID: 24113660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
    Behan MW; Chew DP; Aylward PE
    Curr Opin Cardiol; 2010 Jul; 25(4):321-8. PubMed ID: 20386440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
    Norgard NB; Dinicolantonio JJ
    Postgrad Med; 2013 Jul; 125(4):91-102. PubMed ID: 23933898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
    Robinson A; Das K; Koshy SK; Das P
    Future Cardiol; 2009 May; 5(3):237-46. PubMed ID: 19450050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet options for secondary prevention in acute coronary syndromes.
    Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
    Aronow WS
    Postgrad Med; 2013 Jan; 125(1):51-8. PubMed ID: 23391671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
    Bhatt DL
    Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual antiplatelet therapy in coronary artery disease: a case-based approach.
    Raymond C; Menon V
    Cleve Clin J Med; 2009 Nov; 76(11):663-70. PubMed ID: 19884296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
    Collet JP; Montalescot G
    Hamostaseologie; 2009 Nov; 29(4):339-48. PubMed ID: 19882081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in antiplatelet treatment for acute coronary syndromes.
    Eshaghian S; Shah PK; Kaul S
    Heart; 2010 May; 96(9):656-61. PubMed ID: 19910292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor for acute coronary syndrome?
    Drug Ther Bull; 2011 Jun; 49(6):66-8. PubMed ID: 21632607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events.
    Terpening C
    J Am Board Fam Med; 2009; 22(1):51-6. PubMed ID: 19124633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Wiviott SD
    Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facts and controversies of aspirin and clopidogrel therapy.
    Faxon DP; Freedman JE
    Am Heart J; 2009 Mar; 157(3):412-22. PubMed ID: 19249409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in antiplatelet therapy for acute coronary syndromes.
    Contractor H; Ruparelia N
    Postgrad Med J; 2012 Jul; 88(1041):391-6. PubMed ID: 22357775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.